The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Imagine developing a first-of-its-kind therapy that saved the life of one woman dying from colon cancer, only to lose the financial backing needed to bring it to market. That’s the reality for ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Gene editing can cure illnesses, ensure global food security, conserve species and more. But its risks of misuse are ...

The country's third most valuable company by market cap is a study in contrasts. It's a wealth-altering 13-bagger over the ...

In the ongoing effort to find better ways to fight cancer, scientists have developed a creative approach that uses the body’s ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...